Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Mechlorethamine
Drug ID BADD_D01359
Description A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel on August 23, 2013 for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior skin-directed therapy. Each tube of Valchlor contains 0.016% of mechlorethamine which is equivalent to 0.02% mechlorethamine HCl.
Indications and Usage For the palliative treatment of Hodgkin's disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma. Also for the palliative treatment of metastatic carcinoma resulting in effusion.
Marketing Status approved; investigational
ATC Code L01AA05
DrugBank ID DB00888
KEGG ID D07671
MeSH ID D008466
PubChem ID 4033
TTD Drug ID D03SSE
NDC Product Code Not Available
UNII 50D9XSG0VR
Synonyms Mechlorethamine | Chlormethine | Bis(2-chloroethyl)methylamine | Mustine | Nitrogen Mustard | Chlorethazine | Methylchlorethamine | Cloramin | Embichin | Mechlorethamine Hydrochloride | Hydrochloride, Mechlorethamine | Mechlorethamine Hydrochloride N-Oxide | Hydrochloride N-Oxide, Mechlorethamine | Mechlorethamine Hydrochloride N Oxide | N-Oxide, Mechlorethamine Hydrochloride | NSC-762 | NSC 762 | NSC762 | Mechlorethamine Oxide | Mitomen | Mustargen | Nitrogranulogen | Nitromin | NSC-10107 | NSC 10107 | NSC10107 | Caryolysine | Mechlorethamine N-Oxide | Mechlorethamine N Oxide | Nitrogen Mustard N-Oxide | N-Oxide, Nitrogen Mustard | Nitrogen Mustard N Oxide
Chemical Information
Molecular Formula C5H11Cl2N
CAS Registry Number 51-75-2
SMILES CN(CCCl)CCCl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Superior vena cava syndrome24.04.09.008; 16.32.03.019--
Swelling08.01.03.0150.001007%Not Available
Tenderness08.01.08.0050.000761%Not Available
Therapeutic response decreased08.06.01.0160.000627%Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombophlebitis24.01.02.001--Not Available
Thrombosis24.01.01.006--Not Available
Tinnitus04.04.01.002; 17.04.07.004--
Urticaria23.04.02.001; 10.01.06.0010.001332%
Vertigo17.02.12.002; 04.04.01.003--
Vomiting07.01.07.003--
Seasonal allergy22.04.04.008; 10.01.04.001; 06.04.01.0130.000437%Not Available
Application site vesicles12.07.01.009; 08.02.01.009; 23.03.01.0090.003671%Not Available
Application site dryness23.03.03.024; 12.07.01.011; 08.02.01.0110.002205%Not Available
Peripheral swelling08.01.03.053; 02.05.04.0150.001007%Not Available
Application site inflammation12.07.01.024; 08.02.01.0240.001142%Not Available
Application site papules23.03.03.022; 12.07.01.025; 08.02.01.0250.000951%Not Available
Application site urticaria23.04.02.002; 12.07.01.028; 10.01.06.002; 08.02.01.0280.000381%Not Available
Malignant neoplasm progression16.16.01.0050.000918%Not Available
Ear discomfort04.03.01.0050.000381%Not Available
Application site discharge12.07.01.039; 08.02.01.039; 23.03.03.0490.002149%Not Available
Skin bacterial infection23.11.02.017; 11.02.01.007--Not Available
Musculoskeletal stiffness15.03.05.0270.000817%Not Available
Skin swelling23.03.03.0390.001142%Not Available
Application site swelling12.07.01.027; 08.02.01.0270.001713%Not Available
Skin burning sensation23.03.03.021; 17.02.06.0090.005059%Not Available
Haemorrhage24.07.01.002--Not Available
Pulmonary mass22.02.07.0040.000168%Not Available
Application site discolouration23.03.03.023; 12.07.01.030; 08.02.01.0300.007342%Not Available
Eye injury12.01.04.017; 06.11.01.009--Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages